Matches in SemOpenAlex for { <https://semopenalex.org/work/W2460247604> ?p ?o ?g. }
- W2460247604 endingPage "332" @default.
- W2460247604 startingPage "324" @default.
- W2460247604 abstract "The optimal choice of salvage therapy for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) or Hodgkin lymphoma (HL) remains unknown. Based on promising results of phase II trials, the preferred salvage regimen in British Columbia since 2002 has been the out-patient regimen, gemcitabine, dexamethasone, and cisplatin (GDP). We conducted a retrospective analysis including all patients with relapsed/refractory DLBCL or HL who received GDP as salvage therapy between September 2002 and June 2010. We identified 235 patients: 152 DLBCL, 83 HL. Overall response rates were 49% and 71% for patients with DLBCL and HL, respectively. Within the transplant-eligible population, 52% of patients with DLBCL and 96% of patients with HL proceeded to stem cell transplantation. The 2-year progression-free survival and overall survival were 21% and 28% in the DLBCL cohort, and 58% and 85% in the HL group. GDP is an effective and well-tolerated out-patient salvage regimen for relapsed/refractory DLBCL and HL." @default.
- W2460247604 created "2016-07-22" @default.
- W2460247604 creator A5016787940 @default.
- W2460247604 creator A5017873196 @default.
- W2460247604 creator A5021276970 @default.
- W2460247604 creator A5022658681 @default.
- W2460247604 creator A5023202154 @default.
- W2460247604 creator A5026641386 @default.
- W2460247604 creator A5031758990 @default.
- W2460247604 creator A5037428122 @default.
- W2460247604 creator A5059082232 @default.
- W2460247604 creator A5066770885 @default.
- W2460247604 creator A5074350423 @default.
- W2460247604 creator A5075117420 @default.
- W2460247604 creator A5086115833 @default.
- W2460247604 date "2016-06-27" @default.
- W2460247604 modified "2023-10-14" @default.
- W2460247604 title "Gemcitabine, dexamethasone, and cisplatin (GDP) is an effective and well-tolerated salvage therapy for relapsed/refractory diffuse large B-cell lymphoma and Hodgkin lymphoma" @default.
- W2460247604 cites W1822166136 @default.
- W2460247604 cites W1834370350 @default.
- W2460247604 cites W1881397173 @default.
- W2460247604 cites W1912693401 @default.
- W2460247604 cites W1914654455 @default.
- W2460247604 cites W1954043953 @default.
- W2460247604 cites W1987792231 @default.
- W2460247604 cites W1997353354 @default.
- W2460247604 cites W2058015212 @default.
- W2460247604 cites W2060594675 @default.
- W2460247604 cites W2068410289 @default.
- W2460247604 cites W2084446054 @default.
- W2460247604 cites W2103563361 @default.
- W2460247604 cites W2111716055 @default.
- W2460247604 cites W2112001172 @default.
- W2460247604 cites W2122654415 @default.
- W2460247604 cites W2133345449 @default.
- W2460247604 cites W2140104756 @default.
- W2460247604 cites W2141082026 @default.
- W2460247604 cites W2145010435 @default.
- W2460247604 cites W2145304413 @default.
- W2460247604 cites W2150587745 @default.
- W2460247604 cites W2152518936 @default.
- W2460247604 cites W2157717016 @default.
- W2460247604 cites W2159746531 @default.
- W2460247604 cites W2164526402 @default.
- W2460247604 cites W2300995403 @default.
- W2460247604 cites W2313423582 @default.
- W2460247604 cites W2328676772 @default.
- W2460247604 cites W2343055071 @default.
- W2460247604 cites W4205736005 @default.
- W2460247604 cites W4249283733 @default.
- W2460247604 cites W4293241248 @default.
- W2460247604 doi "https://doi.org/10.1080/10428194.2016.1193852" @default.
- W2460247604 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27347845" @default.
- W2460247604 hasPublicationYear "2016" @default.
- W2460247604 type Work @default.
- W2460247604 sameAs 2460247604 @default.
- W2460247604 citedByCount "26" @default.
- W2460247604 countsByYear W24602476042017 @default.
- W2460247604 countsByYear W24602476042018 @default.
- W2460247604 countsByYear W24602476042019 @default.
- W2460247604 countsByYear W24602476042020 @default.
- W2460247604 countsByYear W24602476042021 @default.
- W2460247604 countsByYear W24602476042022 @default.
- W2460247604 countsByYear W24602476042023 @default.
- W2460247604 crossrefType "journal-article" @default.
- W2460247604 hasAuthorship W2460247604A5016787940 @default.
- W2460247604 hasAuthorship W2460247604A5017873196 @default.
- W2460247604 hasAuthorship W2460247604A5021276970 @default.
- W2460247604 hasAuthorship W2460247604A5022658681 @default.
- W2460247604 hasAuthorship W2460247604A5023202154 @default.
- W2460247604 hasAuthorship W2460247604A5026641386 @default.
- W2460247604 hasAuthorship W2460247604A5031758990 @default.
- W2460247604 hasAuthorship W2460247604A5037428122 @default.
- W2460247604 hasAuthorship W2460247604A5059082232 @default.
- W2460247604 hasAuthorship W2460247604A5066770885 @default.
- W2460247604 hasAuthorship W2460247604A5074350423 @default.
- W2460247604 hasAuthorship W2460247604A5075117420 @default.
- W2460247604 hasAuthorship W2460247604A5086115833 @default.
- W2460247604 hasConcept C126322002 @default.
- W2460247604 hasConcept C141071460 @default.
- W2460247604 hasConcept C142424586 @default.
- W2460247604 hasConcept C143998085 @default.
- W2460247604 hasConcept C2776694085 @default.
- W2460247604 hasConcept C2778559949 @default.
- W2460247604 hasConcept C2779338263 @default.
- W2460247604 hasConcept C2780258809 @default.
- W2460247604 hasConcept C2780401358 @default.
- W2460247604 hasConcept C2780775027 @default.
- W2460247604 hasConcept C2781413609 @default.
- W2460247604 hasConcept C71924100 @default.
- W2460247604 hasConcept C86803240 @default.
- W2460247604 hasConcept C87355193 @default.
- W2460247604 hasConceptScore W2460247604C126322002 @default.
- W2460247604 hasConceptScore W2460247604C141071460 @default.
- W2460247604 hasConceptScore W2460247604C142424586 @default.
- W2460247604 hasConceptScore W2460247604C143998085 @default.
- W2460247604 hasConceptScore W2460247604C2776694085 @default.
- W2460247604 hasConceptScore W2460247604C2778559949 @default.